To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
The UCB-Harvard Research Alliance Expands and Moves Forward
Research collaboration launched to develop novel therapies for the treatment of neurodegenerative disease
19-06-2012: UCB announced that it has launched a second collaborative research project with Harvard that builds upon the Research Alliance signed between UCB and Harvard in 2011. The second research project comprises a collaboration with the laboratory of Junying Yuan, Ph.D., Professor of Cell Biology at Harvard Medical School, aimed at driving translation and developing small molecule compounds for induction of autophagy, with potential applications in the treatment of neurodegenerative diseases.
Autophagy is best described as a mechanism the cell uses to auto-digest intracellular components. It is an evolutionarily conserved catabolic process, mediating the turnover of malfunctioning, aged or damaged proteins and organelles within cells. Autophagy is seen as an important regulator of many critical biological processes. Professor Junying Yuan has been at the forefront of molecular research for over two decades and has received numerous honors and awards in recognition of her work.
The research alliance between Harvard and UCB reflects UCB’s open innovation model that aims to generate new knowledge and capitalize on external scientific advances, resources and expertise through dedicated collaborations that complement the company’s unique internal capabilities and expertise.
The first, ongoing research project funded under the Harvard-UCB alliance is a collaboration with Professor Gökhan S. Hotamisligil, M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, to generate and develop novel antibodies against a target with potential application in a range of diseases including diabetes and other metabolic disorders.
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Vivacta Initiates Development of Point of Care Test for Vitamin D
- 4Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 5A light switch inside the brain
- 6Researchers divide enzyme to conquer genetic puzzle
- 7New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 8Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 9Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 10Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- Malvern Instruments announces global agreement with Proveris Scientific
- Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
- Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing C ...
- Belfer Institute and Evotec establish collaboration in oncology
- BRAIN-led industrial NatLifE 2020 innovation alliance started after receipt ...
- New angle to combat malignant brain tumors in children
- Ablynx and Spirogen enter in research collaboration for toxin-nanobody drug conjugates
- Bone Therapeutics Invests in Cell Therapy Manufacturing Facility
- Cell therapy a little more concrete thanks to VIB research
- Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome